Johnson & Johnson Stock Rises 0.36% with 8.19 Billion Trading Volume Ranking 83rd

On April 29, 2025, Johnson & Johnson (JNJ) saw a trading volume of 8.19 billion, ranking 83rd in the day's stock market. The stock rose by 0.36%, marking its second consecutive day of gains, with a total increase of 0.86% over the past two days.

Johnson & Johnson's TAR-200 monotherapy has shown promising results in achieving high disease-free survival rates in patients with BCG-unresponsive, high-risk papillary non-muscle-invasive bladder cancer (NMIBC). The treatment demonstrated over 80% disease-free survival at nine months, indicating its potential as a monotherapy option for this patient population.

Johnson & Johnson will present at the Bernstein’s 41st Annual Strategic Decisions Conference on May 28, 2025. The company's management will participate in a Fireside Chat at 10:00 a.m. Eastern Time, providing insights into their strategic vision and future plans. A live audio webcast of the presentation will be available on Johnson & Johnson’s Investor Relations website, with an archived version to be made available later that day.